Nectin-4 — Drug Target

All drugs that target Nectin-4 — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Monoclonal antibody-drug conjugate

Marketed (4)

• Padcev · Astellas Pharma · Oncology
  Padcev works by binding to Nectin-4 on the surface of cancer cells, marking them for destruction.
• Padcev Ejfv · Astellas Pharma · Oncology
  Enfortumab vedotin-ejfv binds to Nectin-4, internalizes, releases MMAE, disrupting microtubules and causing cell death.
• ENFORTUMAB VEDOTIN
  Enfortumab vedotin-ejfv binds to Nectin-4 on cancer cells, internalizes, releases MMAE, disrupting microtubules and causing cell death.
• Enfortumab · Astellas Pharma · Oncology

Phase 3 pipeline (1)

• enfortumab vedotin (EV) · Astellas Pharma Global Development, Inc. · Monoclonal antibody-drug conjugate · Oncology
  Enfortumab vedotin is a monoclonal antibody-drug conjugate that targets Nectin-4, a protein highly expressed on the surface of certain cancer cells.

Phase 2 pipeline (1)

• Enfortumab Vedotin-Ejfv · Mirati Therapeutics Inc. · Monoclonal antibody-drug conjugate · Oncology
  Enfortumab vedotin-ejfv is a monoclonal antibody-drug conjugate that targets Nectin-4.